XML 61 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 21, 2025
Jun. 30, 2024
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Trading Symbol CALC    
Entity Registrant Name CalciMedica, Inc.    
Entity Central Index Key 0001534133    
ICFR Auditor Attestation Flag false    
Document financial statement error correction false    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Common Stock, Shares Outstanding   13,481,917  
Entity Public Float     $ 27.9
Entity File Number 001-39538    
Entity Tax Identification Number 45-2120079    
Entity Address, Address Line One 505 Coast Boulevard South    
Entity Address, Address Line Two Suite 307    
Entity Address, City or Town La Jolla    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92037    
City Area Code 858    
Local Phone Number 952-5500    
Entity Interactive Data Current Yes    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code DE    
Document Annual Report true    
Document Transition Report false    
Auditor Name Ernst & Young LLP    
Auditor Firm ID 42    
Auditor Location San Diego, California    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive Proxy Statement (the “Proxy Statement”) for the 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission not later than April 30, 2025 are incorporated by reference into Part III of this Annual Report on Form 10-K 		   
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of CalciMedica, Inc. (and subsidiaries)(the Company) as of December 31, 2024, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ equity and cash flows for the year then ended, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of CalciMedica, Inc. (the Company) as of December 31, 2023, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ equity (deficit) and cash flows for the year ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.

    
Subsidiaries [Member]      
Document Information [Line Items]      
Auditor Name Moss Adams LLP    
Auditor Firm ID 659    
Auditor Location San Diego, California